Targeting CA19-9 for Imaging Pancreas Cancer
Author Information
Author(s): Mark D. Girgis, Tove Olafsen, Vania Kenanova, Katelyn E. McCabe, Anna M. Wu, James S. Tomlinson
Primary Institution: UCLA
Hypothesis
Can CA19-9 be effectively targeted with a radiolabeled antibody for imaging pancreas cancer?
Conclusion
The study demonstrates the potential of using a radiolabeled anti-CA19-9 antibody for imaging pancreas cancer.
Supporting Evidence
- CA19-9 is expressed in more than 90% of pancreatic cancer cases.
- The average tumor to blood ratio was 5.0.
- 12 out of 14 human pancreatic adenocarcinoma specimens evaluated were positive for CA19-9 expression.
- Immunoreactivity of the radiolabeled fraction was 60%.
- Average blood CA19-9 level for mice with antigen-positive xenografts was 45 units/mL.
Takeaway
This study shows that a special antibody can help doctors see pancreas cancer better by sticking to a specific marker on the cancer cells.
Methodology
The study used flow cytometry to quantify CA19-9 on cancer cells, labeled an antibody with Iodine-124, and performed microPET imaging on mice with cancer xenografts.
Limitations
The intact antibody's large size may lead to high background signals, reducing imaging contrast.
Statistical Information
P-Value
0.056
Statistical Significance
p=0.056
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website